About Biogenity

Your expression data analyst

The company

Biogenity was founded in the summer of 2018 and is a biotechnology company focusing on expression data analysis for the preclinical-phases.

A need for smarter analysis

The omics technologies are advancing vastly and dominating discovery-based studies for biomarkers. These methods can deliver above 10.000 readings per sample, thus generating a large amount of data, which can be overwhelming for the researcher if not a data-specialist.

Our vision

Biogenity's vision is to make data easy to manage and interpret. Thus a deeper and more precise understanding of the data is provided. We will achieve this by making advanced data analyzes accessible for all sizes of enterprises and researchers with one mission: To fuel and focus the search of new biomarkers for disease and better treatments hereof.

Corporate Management

K. Kastaniegaard
Kenneth Kastaniegaard
CEO & Co-Founder

Ph.D. in Biomedical Science and Engineering

Phone: (+45) 71110509
Email: kkas@biogenity.com

L. Loeb
Louis Loeb
CCO & Co-Founder

MSc in Information Technology

Phone: (+45) 71116050
Email: louis@biogenity.com

Our Products

We base large parts of our product development on our unique pipeline. It can automate much of the process during data analysis by using the right tests for decision making. The programming behind the technology has been developed in-house, still based on the state of the art biostatistical methods and machine learning.

Powered by The Next-Generation Engine

At Biogenity, we have developed our expression engine, which we in daily terms call NGEN. This powerful engine uses machine learning to sort and analyze your data; making all the right analytical decisions when processing.

The Next-Generation Engine allows automating otherwise monotonous and time-consuming tasks when processing expression data. The result hereof is a premium analysis at a low cost.

New products in development

We keep optimizing our products to include more types of expression analyzes and make sure the methods used are up-to-date. We strive to ensure our customers to have the best possible understanding of their data to generate their hypotheses and conclusions.

Searching partners for

Using big data for biomarker-validation

We are also developing pipelines to utilize artificial intelligence-based methods to bring big data into personalized medicine. It is our goal to make big data a usable tool for biomarker-validation and discovery accessible for all sizes of Enterprises and researchers.

Become a beta tester

Advisory Board

Advisory Board
Jesper Kihl
Former Vice President, Regulatory Affairs at
Novo Nordisk &
LEO Pharma
Advisory Board
Søren Nielsen
CEO at
Advisory Board
Christian Vinther
Investor Relations Manager at

Business Partners

2A Pharma
Meta IQ


Open Entrepreneurship
Innovations Fund Denmark
Aalborg University
Aarhus University
Erhvervshus Nordjylland

Funds and Incubators

Horizon 2020
InnoFounder - Graduate
Innovativ Vækst

Subscribe to our Newsletter

Get updates about the development of new data analytic pipelines and new big data-based approached to discover and validate biomarkers, special offers and when we seek partners for new projects.

How often do I get a Newsletter?

We know how annoying overuse of newsletters can be - which is why we only send five a year.

By subscribing you agree to our privacy policy.

Talk with our expert

By requesting you agree to our privacy policy.